Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

Record History

See every version on ClinicalTrials.gov ↗

1. Stopped Oct 13, 2026 Trial terminated Sponsor's reason: The study terminated due to a business decision. The decision to terminate the trial was not based on any safety concerns. Show 4 more changesShow less

   • Trial sites reduced: 31 → 24 locations
   • Final enrollment: 61 participants (planned 91)
   • Primary completion date changed from estimate of Aug 2, 2028 to Sep 23, 2026
   • Eligibility criteria shortened, about 19 words
2. Minor May 11, 2026 Trial sites expanded: 16 → 31 locationsv48
3. Minor May 4, 2026 Trial sites reduced: 31 → 16 locationsv47
4. Notable Apr 13, 2026 Primary and study completion pushed from Oct 1, 2027 to Aug 2, 2028

   • Trial arms changed: 3 → 4
   • Study description shortened, about 1 word

   v46
5. Minor Apr 6, 2026 Study sites: 30 to 31v45
6. Minor Mar 31, 2026 Enrollment increased: 61 → 91 participants

   • Trial sites expanded: 26 → 30 locations

   v44
7. Minor Feb 12, 2026 Study sites: 28 to 26v43
8. Minor Aug 12, 2025 Re-verified, no change to tracked fieldsv42
9. Minor Jun 27, 2025 Study sites: 26 to 28v41
10. Minor May 20, 2025 Primary and study completion dates: Oct 28, 2027 to Oct 1, 2027

    • Site details revised at 1 of 26 sites

    v40
11. Notable Apr 9, 2025 Primary and study completion dates: Oct 27, 2026 to Oct 28, 2027

    • Study sites: 30 to 26

    v39
12. Minor Oct 23, 2024 Secondary endpoints: details revised at 1 of 6 entries

    • Study sites revised (30)
    • Study arms: 2 to 3
    • Study description expanded, about 4 words

    v38
13. Minor Jul 17, 2024 Primary and study completion dates: May 17, 2027 to Oct 27, 2026

    • Study sites revised (30)

    v37
14. Notable Apr 23, 2024 Primary and study completion dates: Mar 21, 2025 to May 17, 2027v36
15. Minor Jan 12, 2024 Study sites: 29 to 30v35
16. Minor Sep 15, 2023 Re-verified, no change to tracked fieldsv34
17. Minor Aug 21, 2023 Site details revised at 2 of 29 sitesv33
18. Minor Jul 17, 2023 Site details revised at 2 of 29 sitesv32
19. Minor Jun 21, 2023 Site details revised at 7 of 29 sitesv31
20. Minor May 30, 2023 Site details revised at 2 of 29 sitesv30
21. Notable Apr 17, 2023 Trial status: Suspended to Recruiting

    • Study sites: 28 to 29

    v29
22. Minor Mar 17, 2023 Study sites revised (28)v28
23. Notable Feb 28, 2023 Primary and study completion dates: Oct 22, 2023 to Mar 21, 2025v27
24. Stopped Jan 25, 2023 Trial status: Recruiting to Suspended Sponsor's reason: pause for interim analysis.v26 Show 6 more changesShow less

    • Enrollment target: 40 to 61
    • Primary endpoint revised
    • Secondary endpoints revised (6)
    • Study description expanded, about 13 words
    • Site details revised at 28 of 28 sites
    • Study arms: 1 to 2
25. Minor Jan 9, 2023 Study sites: 27 to 28v25
26. Minor Dec 6, 2022 Study sites: 26 to 27v24
27. Minor Nov 29, 2022 Study sites: 25 to 26v23
28. Minor Nov 7, 2022 Study sites revised (25)v22
29. Minor Oct 26, 2022 Study sites: 24 to 25v21
30. Minor Oct 24, 2022 Study sites: 23 to 24v20
31. Minor Oct 17, 2022 Site details revised at 1 of 23 sitesv19
32. Minor Oct 7, 2022 Re-verified, no change to tracked fieldsv18
33. Minor Sep 21, 2022 Study sites: 22 to 23v17
34. Minor Sep 13, 2022 Study sites: 20 to 22v16
35. Minor Aug 23, 2022 Study sites: 18 to 20v15
36. Minor Jul 26, 2022 Site details revised at 2 of 18 sitesv14
37. Minor Jul 5, 2022 Study sites: 17 to 18v13
38. Minor Jun 9, 2022 Study sites: 16 to 17v12
39. Minor May 27, 2022 Study sites: 14 to 16v11
40. Minor Apr 8, 2022 Study sites: 13 to 14v10
41. Minor Apr 4, 2022 Study sites: 12 to 13v9
42. Minor Mar 28, 2022 Study sites: 7 to 12v8
43. Notable Feb 11, 2022 Trial status: Not Yet Recruiting to Recruiting

    • Start date changed from estimate of Jan 31, 2022 to Feb 2, 2022
    • Site details revised at 7 of 7 sites

    v7
44. Minor Jan 26, 2022 Study sites: 6 to 7v6
45. Minor Jan 20, 2022 Study sites: 4 to 6v5
46. Notable Jan 12, 2022 Start date: Nov 15, 2021 to Jan 31, 2022v4
47. Minor Nov 17, 2021 Study sites: 1 to 4v3
48. Minor Nov 4, 2021 Study sites: 0 to 1

    • Start date: Nov 14, 2021 to Nov 15, 2021

    v2
49. Minor Sep 27, 2021 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.